Anyone, of any ethnicity, can get cystic fibrosis. But for decades it has been overlooked in people of color, leading to misdiagnoses and dismal health disparities. Terry Wright takes a pulmonary ...

Nerandomilast has been shown to slow the progression of idiopathic pulmonary fibrosis, but an assessment of its effects in other types of progressive pulmonary fibrosis is needed. In a phase 3 ...

In a Stanford-led study published in Nature, researchers detailed a new strategy to beat cardiac fibrosis, a condition with no current treatment that is characterized by scarring of the heart tissue.

Sering mual dan perih di lambung? Cek daftar pantangan makanan dan minuman yang harus dihindari penderita GERD. Penyakit asam lambung atau GERD (Gastroesophageal Reflux Disease) sering menimbulkan ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Cystic fibrosis is a genetic disorder that affects roughly 40,000 Americans. The condition is caused by a mutation in the patient's cystic fibrosis transmembrane conductance regulator (CFTR) gene, ...

In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks. In this phase 3, double-blind trial ...

The trial enrolled 1176 patients across 44 countries with fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), such as autoimmune ILDs, hypersensitivity pneumonitis, and unclassifiable ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype ...

Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology ...